Trafermin
Also known as: Basic Fibroblast Growth Factor, bFGF, FGF-2, FGF‑2, Fiblast, Fiblast Spray, Recombinant Human bFGF, Trafermin
Source Trafermin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human basic fibroblast growth factor (Trafermin) formulated as a topical spray for the treatment of skin ulcers and chronic wounds. Promotes granulation tissue formation and re‑epithelialization.
Mechanism of Action
Binds to FGFR1-4 receptors, activating MAPK/ERK and PI3K/Akt pathways to stimulate fibroblast proliferation, angiogenesis, and extracellular matrix synthesis, thereby accelerating wound repair.
Routes of Administration
Goals & Uses
- Pressure ulcer / skin ulcer healingWound HealingHigh
- Burn wound healingWound HealingModerate
- Angiogenesis promotion in ischemic tissueCardiovascular / IschemiaLow
- Accelerate wound healingWound CareModerate
- Periodontal tissue regenerationDentistry / RegenerationModerate
- Diabetic foot ulcer treatmentWound HealingModerate
- Promote granulation tissue formationTissue RegenerationModerate
Contraindications
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Hypersensitivity to trafermin or excipientsAllergyHigh
- Known malignancy or tumor at wound siteOncologyHigh
- Known hypersensitivity to recombinant bFGFAllergyHigh
- Active malignant neoplasmOncologyHigh
Adverse Effects
- Hypersensitivity / allergic reactionImmunologicalRare
- Contact dermatitisDermatologicalUncommon
- Wound exudate increaseLocal ReactionCommon
- Local erythemaDermatologicCommon
- Application site erythema / irritationLocal ReactionCommon
- FeverSystemicUncommonElevated body temperature
- Hypersensitivity systemic reactionSystemicRare
Drug Interactions
- HeparinLow
- Corticosteroids (topical)Low
- Bevacizumab (anti‑VEGF)Moderate
Population Constraints
- Pediatric patientsAgeRelative
- Patients with active cancerOncologicalAbsolute
- Pediatric patients (<12 y)AgeRelative
- Elderly patients (>75 y)AgeRelative
- Elderly patients with multiple comorbiditiesAge / ComorbidityRelative
Regulatory Status
- European UnionUnapprovedNo EMA approval; only clinical research.
- JPApprovedApproved: skin ulcer, chronic woundMarketed as Fiblast spray.
- United StatesUnapprovedInvestigational; not FDA‑approved.
- United KingdomUnapprovedNot approved by the MHRA. No marketing authorization in the UK.
Approved in Japan (Ministry of Health, Labour and Welfare) for skin ulcer therapy; not approved in the US or EU.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Trafermin?
Recombinant human basic fibroblast growth factor (Trafermin) formulated as a topical spray for the treatment of skin ulcers and chronic wounds. Promotes granulation tissue formation and re‑epithelialization.
What is Trafermin used for?
Trafermin is educationally associated with: Pressure ulcer / skin ulcer healing, Burn wound healing, Angiogenesis promotion in ischemic tissue, Accelerate wound healing, Periodontal tissue regeneration, Diabetic foot ulcer treatment, Promote granulation tissue formation. Educational only — not medical advice.
How is Trafermin administered?
Recorded routes of administration: Intravenous, Subcutaneous, Topical.
What are the potential side effects of Trafermin?
Reported adverse effects include: Hypersensitivity / allergic reaction, Contact dermatitis, Wound exudate increase, Local erythema, Application site erythema / irritation, Fever, Hypersensitivity systemic reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid Trafermin?
Recorded contraindications: Pregnancy, Hypersensitivity to trafermin or excipients, Known malignancy or tumor at wound site, Known hypersensitivity to recombinant bFGF, Active malignant neoplasm. Consult a qualified clinician before use.